National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Alutard SQ® honey bee and Alutard SQ® wasp venoms are licensed as allergy immunotherapies for patients with a documented history of generalised and/or systemic IgE-mediated allergic reactions due to sensitisation to honey bee venom (Apis mellifera) and wasp venom (Vespula spp.), respectively.

 

NCPE Assessment Process Complete
Rapid review commissioned 04/02/2020
Rapid review completed 10/03/2020
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that Alutard SQ® honey bee venom and Alutard SQ® wasp venom be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.